

Maryjane A Farr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7691976/publications.pdf>

Version: 2024-02-01

101
papers

3,375
citations

159585

30
h-index

161849

54
g-index

102
all docs

102
docs citations

102
times ranked

5108
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation, 2020, 20, 1800-1808.	4.7	683
2	Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1165.	6.1	170
3	Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. Journal of Heart and Lung Transplantation, 2012, 31, 601-610.	0.6	154
4	Hepatic Dysfunction in Ambulatory Patients With Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2253-2261.	2.8	145
5	A change of heart: Preliminary results of the US 2018 adult heart allocation revision. American Journal of Transplantation, 2020, 20, 2781-2790.	4.7	113
6	Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 540-545.	0.6	107
7	North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, 1636-1662.e36.	4.4	95
8	Serial Echocardiography Using Tissue Doppler and Speckle Tracking Imaging to Monitor Right Ventricular Failure Before and After Left Ventricular Assist Device Surgery. JACC: Heart Failure, 2013, 1, 216-222.	4.1	90
9	Improved outcomes from extracorporeal membrane oxygenation versus ventricular assist device temporary support of primary graft dysfunction in heart transplant. Journal of Heart and Lung Transplantation, 2017, 36, 650-656.	0.6	88
10	Sex-Related Differences in Use and Outcomes of Left Ventricular Assist Devices as Bridge to Transplantation. JACC: Heart Failure, 2019, 7, 250-257.	4.1	66
11	Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. Journal of Heart and Lung Transplantation, 2020, 39, 880-890.	0.6	65
12	Socioeconomic Disparities in Adherence and Outcomes After Heart Transplant. Circulation: Heart Failure, 2018, 11, e004173.	3.9	59
13	Left Ventricular Longitudinal Strain by Speckle-Tracking Echocardiography is Associated With Treatment-Requiring Cardiac Allograft Rejection. Journal of Cardiac Failure, 2014, 20, 359-364.	1.7	58
14	Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Cardiology, 2020, 5, 1048.	6.1	58
15	Risk of severe primary graft dysfunction in patients bridged to heart transplantation with continuous-flow left ventricular assist devices. Journal of Heart and Lung Transplantation, 2018, 37, 1433-1442.	0.6	49
16	Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. Circulation, 2019, 140, 459-469.	1.6	49
17	Minimally invasive CentriMag ventricular assist device support integrated with extracorporeal membrane oxygenation in cardiogenic shock patients: a comparison with conventional CentriMag biventricular support configuration. European Journal of Cardio-thoracic Surgery, 2017, 52, 1055-1061.	1.4	48
18	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. American Journal of Transplantation, 2020, 20, 3198-3205.	4.7	48

#	ARTICLE	IF	CITATIONS
19	Challenges in Heart Transplantation in the Era of COVID-19. <i>Circulation</i> , 2020, 141, 2048-2051.	1.6	47
20	Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study. <i>Transplant Infectious Disease</i> , 2021, 23, e13637.	1.7	47
21	Ventricular Assist Device Utilization in Heart Transplant Candidates. <i>Circulation: Heart Failure</i> , 2018, 11, e004586.	3.9	44
22	Extracorporeal membrane oxygenation for primary graft dysfunction after heart transplant. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 1576-1584.e3.	0.8	44
23	Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1226-1233.	0.6	42
24	Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. <i>American Journal of Transplantation</i> , 2021, 21, 2254-2261.	4.7	40
25	Heart or lung transplant outcomes in HIV-infected recipients. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1296-1305.	0.6	37
26	Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 862-870.	0.6	36
27	The new United States heart allocation policy: Progress through collaborative revision. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 595-596.	0.6	34
28	Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1215-1222.	0.6	33
29	Psychosocial Risk and Its Association With Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. <i>Circulation: Heart Failure</i> , 2020, 13, e006910.	3.9	33
30	Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis. <i>International Journal of Cardiology</i> , 2018, 265, 71-76.	1.7	32
31	Incidence and Impact of On-Cardiopulmonary Bypass Vasoplegia During Heart Transplantation. <i>ASAIO Journal</i> , 2018, 64, 43-51.	1.6	32
32	Dobutamine stress echocardiography is inadequate to detect early cardiac allograft vasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1040-1041.	0.6	31
33	Outcomes of Adult Patients With Congenital Heart Disease After Heart Transplantation: Impact of Disease Type, Previous Thoracic Surgeries, and Bystander Organ Dysfunction. <i>Journal of Cardiac Failure</i> , 2016, 22, 578-582.	1.7	30
34	Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition. <i>American Journal of Transplantation</i> , 2020, 20, 3620-3630.	4.7	27
35	Comparative Assessment of Anti-HLA Antibodies Using Two Commercially Available Luminex-Based Assays. <i>Transplantation Direct</i> , 2017, 3, e218.	1.6	25
36	Potential for donation after circulatory death heart transplantation in the United States: Retrospective analysis of a limited UNOS dataset. <i>American Journal of Transplantation</i> , 2020, 20, 525-529.	4.7	23

#	ARTICLE	IF	CITATIONS
37	Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2018, 11, e004665.	3.9	22
38	Profiling non-HLA antibody responses in antibody-mediated rejection following heart transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 2571-2580.	4.7	22
39	A continuous-flow external ventricular assist device for cardiogenic shock: Evolution over 10 years. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 157-165.e1.	0.8	21
40	Impact of Temporary Percutaneous Mechanical Circulatory Support Before Transplantation in the 2018 Heart Allocation System. <i>JACC: Heart Failure</i> , 2022, 10, 12-23.	4.1	21
41	Recovery With Temporary Mechanical Circulatory Support While Waitlisted for Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2022, 79, 900-913.	2.8	20
42	Incidence and risk factors of groin lymphocele formation after venoarterial extracorporeal membrane oxygenation in cardiogenic shock patients. <i>Journal of Vascular Surgery</i> , 2018, 67, 542-548.	1.1	19
43	Extracorporeal photopheresis and its role in heart transplant rejection: prophylaxis and treatment. <i>Clinical Transplantation</i> , 2021, 35, e14333.	1.6	19
44	Advanced Therapies for Advanced Heart Failure in Women. <i>Heart Failure Clinics</i> , 2019, 15, 97-107.	2.1	18
45	Transition of a Large Tertiary Heart Failure Program in Response to the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007516.	3.9	17
46	Practice Patterns Surrounding Pregnancy After Heart Transplantation. <i>Circulation: Heart Failure</i> , 2020, 13, e006811.	3.9	17
47	Evolving Characteristics of Heart Transplantation Donors and Recipients. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1108-1123.	2.8	16
48	Infectious complications after cardiac transplantation in patients bridged with mechanical circulatory support devices versus medical therapy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1116-1123.	0.6	15
49	Outcomes after heart transplantation for AL compared to ATTR cardiac amyloidosis. <i>Clinical Transplantation</i> , 2020, 34, e14028.	1.6	15
50	Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation. <i>PLoS ONE</i> , 2020, 15, e0233646.	2.5	15
51	Predictors of Survival for Patients with Acute Decompensated Heart Failure Requiring Extra-Corporeal Membrane Oxygenation Therapy. <i>ASAIO Journal</i> , 2019, 65, 781-787.	1.6	14
52	Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system. <i>Clinical Transplantation</i> , 2020, 34, e14109.	1.6	14
53	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009203.	4.8	14
54	Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis. <i>Circulation: Heart Failure</i> , 2021, 14, e007909.	3.9	14

#	ARTICLE	IF	CITATIONS
55	Impact of UNOS allocation policy changes on utilization and outcomes of patients bridged to heart transplant with intra-aortic balloon pump. <i>Clinical Transplantation</i> , 2022, 36, e14533.	1.6	14
56	Recent Advances in the Diagnosis and Management of Cirrhosis-Associated Cardiomyopathy in Liver Transplant Candidates: Advanced Echo Imaging, Cardiac Biomarkers, and Advanced Heart Failure Therapies. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8s1, CMC.S15722.	1.8	13
57	Vascular inflammation and abnormal aortic histomorphometry in patients after pulsatile- and continuous-flow left ventricular assist device placement. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1085-1091.	0.6	13
58	Management of primary graft failure after heart transplantation: Preoperative risks, perioperative events, and postoperative decisions. <i>Clinical Transplantation</i> , 2019, 33, e13557.	1.6	13
59	Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?. <i>Circulation: Heart Failure</i> , 2021, 14, e007916.	3.9	13
60	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. <i>Journal of Cardiac Failure</i> , 2022, 28, 1149-1157.	1.7	12
61	Cardiac Implantable Electronic Devices Following Heart Transplantation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1028-1042.	3.2	11
62	Association between recipient blood type and heart transplantation outcomes in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 363-370.	0.6	11
63	Outcomes of bridge to cardiac retransplantation in the contemporary mechanical circulatory support era. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 171-181.e1.	0.8	10
64	T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathy. <i>American Journal of Transplantation</i> , 2021, 21, 1465-1476.	4.7	10
65	Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction. <i>Clinical Transplantation</i> , 2020, 34, e13779.	1.6	9
66	PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature. <i>Transplantation</i> , 2020, 104, e38-e39.	1.0	9
67	Outcomes of Heart Transplantation in Adult Congenital Heart Disease With Prior Intracardiac Repair. <i>Annals of Thoracic Surgery</i> , 2021, 112, 846-853.	1.3	9
68	De Novo Human Leukocyte Antigen Allosensitization in Heartmate 3 Versus Heartmate II Left Ventricular Assist Device Recipients. <i>ASAIO Journal</i> , 2022, 68, 226-232.	1.6	9
69	Transcriptomic heterogeneity of antibody mediated rejection after heart transplant with or without donor specific antibodies. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1472-1480.	0.6	9
70	Surveillance for disease progression of transthyretin amyloidosis after heart transplantation in the era of novel disease modifying therapies. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 199-207.	0.6	9
71	Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab. <i>Circulation Journal</i> , 2015, 79, 368-374.	1.6	8
72	<sc>VA</sc>â€<sc>ECMO</sc> for cardiogenic shock in the contemporary era of heart transplantation: Which patients should be urgently transplanted?. <i>Clinical Transplantation</i> , 2018, 32, e13356.	1.6	8

#	ARTICLE	IF	CITATIONS
73	Desensitization in the Era of Precision Medicine: Moving From the Bench to Bedside. <i>Transplantation</i> , 2019, 103, 1574-1581.	1.0	8
74	Minimally invasive central venoarterial extracorporeal membrane oxygenation for long-term ambulatory support as a bridge to heart-lung transplant. <i>Journal of Artificial Organs</i> , 2020, 23, 394-396.	0.9	8
75	Changes in waitlist and posttransplant outcomes in patients with adult congenital heart disease after the new heart transplant allocation system. <i>Clinical Transplantation</i> , 2021, 35, e14458.	1.6	8
76	Heart Xenotransplant: A Door That Is Finally Opening. <i>Circulation</i> , 2022, 145, 871-873.	1.6	8
77	Impact of Induction Immunosuppression on Post-Transplant Outcomes of Patients Bridged with Contemporary Left Ventricular Assist Devices. <i>ASAIO Journal</i> , 2020, 66, 261-267.	1.6	6
78	Left and Right Ventricular Functional Dynamics Determined by Echocardiograms Before and After Lung Transplantation. <i>American Journal of Cardiology</i> , 2015, 116, 652-659.	1.6	5
79	Cardiac transplantation in adult congenital heart disease with prior sternotomy. <i>Clinical Transplantation</i> , 2021, 35, e14229.	1.6	5
80	Critically appraising the 2018 United Network for Organ Sharing donor allocation policy. <i>Current Opinion in Anaesthesiology</i> , 2021, Publish Ahead of Print, .	2.0	5
81	Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients. <i>Progress in Transplantation</i> , 2019, 29, 129-134.	0.7	4
82	C-Reactive Protein Levels Predict Outcomes in Continuous-Flow Left Ventricular Assist Device Patients. <i>ASAIO Journal</i> , 2021, Publish Ahead of Print, 884-890.	1.6	4
83	Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008968.	3.9	4
84	Impact of Sharing O Heart With Non-O Recipients: Simulation in the United Network for Organ Sharing Registry. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1356-1363.	1.3	3
85	Impact of socioeconomic deprivation on evaluation for heart transplantation at an urban academic medical center. <i>Clinical Transplantation</i> , 2022, 36, e14652.	1.6	3
86	Biomarker-Based Assessment for Infectious Risk Before and After Heart Transplantation. <i>Current Heart Failure Reports</i> , 0, , .	3.3	3
87	Considerations for Referral: What Happens to Patients After Being Turned Down for Left Ventricular Assist Device Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 300-307.	1.7	2
88	Effect of Pulmonary Hypertension on Transplant Outcomes in Patients With Ventricular Assist Devices. <i>Annals of Thoracic Surgery</i> , 2020, 110, 158-164.	1.3	2
89	Advanced heart failure patients supported with ambulatory inotropic therapy: What defines success of therapy?. <i>American Heart Journal</i> , 2021, 239, 11-18.	2.7	2
90	The Role of Serial Right Heart Catheterization Survey in Patients Awaiting Heart Transplant on Ventricular Assist Device. <i>ASAIO Journal</i> , 2021, Publish Ahead of Print, .	1.6	2

#	ARTICLE	IF	CITATIONS
91	Deep vein thrombosis and pulmonary embolism after heart transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14705.	1.6	2
92	Outcomes of mechanical support for cardiogenic shock associated with late cardiac allograft failure. <i>Journal of Cardiac Surgery</i> , 2020, 35, 3381-3386.	0.7	1
93	Chronic intermittent intravenous immunoglobulin in heart transplant recipients with elevated donor-specific antibody levels. <i>Clinical Transplantation</i> , 2021, , e14524.	1.6	1
94	Letter by Clerkin et al Regarding Article, "Importance of Routine Antihuman/Leukocyte Antibody Monitoring: De Novo Donor Specific Antibodies Are Associated With Rejection and Allograft Vasculopathy After Heart Transplantation" • <i>Circulation</i> , 2018, 137, 1870-1871.	1.6	0
95	A Pioneer in Transplantation Genomics, Inclusion, and Diversity: A Conversation With Hannah Valantine, MBBS, MD. <i>Circulation</i> , 2021, 143, 2321-2326.	1.6	0
96	How can we better inform our patients about post-heart transplantation survival? A conditional survival analysis. <i>Clinical Transplantation</i> , 2021, 35, e14449.	1.6	0
97	Local competition influences donor heart acceptance practice. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 835-838.	0.6	0
98	A Foot Soldier in Cardiac Metabolism: A Conversation With Heinrich Taegtmeyer, MD, DPhil. <i>Circulation</i> , 2021, 144, 1659-1663.	1.6	0
99	Abstract 21416: Variation Across Centers and Predictors of Initial Immunosuppression Strategy After Heart Transplant. <i>Circulation</i> , 2017, 136, .	1.6	0
100	Abstract 21394: Socioeconomic and Racial Disparities in Outcomes Among Patients Listed for Heart Transplant in the United States. <i>Circulation</i> , 2017, 136, .	1.6	0
101	Abstract 21350: Outcomes With Steroid-Free Maintenance Immunosuppression After Heart Transplant: Results From the United Network for Organ Sharing Registry. <i>Circulation</i> , 2017, 136, .	1.6	0